Novartis (NYSE:NVS) announces five-year
follow-up data from its COMBI-AD study evaluating the combination of
Tafinlar (dabrafenib) and Mekinist (trametinib) in high-risk stage III
BRAF mutation-positive melanoma patients following the surgical removal
of the cancer.
At year 5, 52% of the patients who received
adjuvant treatment with the doublet therapy were alive and relapse-free
compared to 36% of patients receiving placebo after surgery.
Median relapse-free survival (RFS) was not reached at the five-year data cutoff.
Shares up 2% premarket.
#ASCO20
https://seekingalpha.com/news/3578650-novartis-tafinlar-mekinist-shows-long-term-survival-benefit-in-melanoma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.